Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Inv. presentation
Quarterly results

Inmune Bio, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
06/06/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "INmune Bio to present Alzheimer’s Drug Candidate XPro1595 at The TNF Conference on June 4, 2019"
06/04/2019 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
05/29/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "INmune Bio to Present at the 9th Annual LD Micro Invitational on June 5th"
05/24/2019 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Sublease between INmune Bio Inc. and CTI-Clinical Trial Services, Inc"
05/17/2019 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Amendment to Securities Purchase Agreement between INmune Bio, Inc. and Raymond J. Tesi",
"Amendment to Securities Purchase Agreement between INmune Bio, Inc. and David J. Moss"
05/16/2019 8-K Quarterly results
Docs: "Purchase Agreement between INmune Bio Inc. and Lincoln Park Capital Fund, LLC",
"Registration Rights Agreement between INmune Bio Inc. and Lincoln Park Capital Fund, LLC",
"INmune Bio Reports First Quarter 2019 Financial Results and Provides Shareholder Update GlobeNewswire",
"INmune Bio, Inc."
05/13/2019 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat...
Docs: "EX - 99.1"
05/06/2019 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities
04/29/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "Waiver from Pacific Seaboard Investments Ltd"
04/19/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "INmune Bio Presenting Poster at the Neuroimmunology Drug Development Summit LA JOLLA, Calif., April 17, 2019 -- INmune Bio, Inc. , an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that Christopher Barnum, Ph.D., Director of Neuroscience and Translational Medicine, will be presenting a poster at the Neuroimmunology Drug Development Summit in Boston on April 17. The poster will address the Phase 1b trial on the company’s drug candidate XPro1595 for patients with mild to moderate Alzheimer’s disease. ”Because of our focus on neuroinflammation as a cause of neurologic disease, we have designed a Phase 1 trial that measures traditional and novel biomarkers of inflammation as a first step in our Alzheimer’s d..."
04/12/2019 8-K Quarterly results
04/04/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "NASDAQ Closing Bell Release"
03/13/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Website Release"
02/13/2019 8-K Quarterly results
02/08/2019 8-K Quarterly results
02/08/2019 8-K Quarterly results
02/06/2019 8-K Quarterly results
01/17/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "INmune Bio Contact: David Moss CFO 964-3720 [email protected] Investors: LHA Investor Relations Miriam Weber Miller Senior Vice President 838-3777 [email protected] Ascent Investor Relations"

Rocket Data Systems, Inc. © 2018 | Contact Us | Data Disclaimer | Terms of Use | Privacy